.jpg)
POLYAMINE DERIVATIVES WITH ANTIPARASITIC ACTIVIT
WO22008784
PCT/ES2021/070503
The present invention has demonstrated the usefulness of polyamine compounds in the treatment of parasitic diseases of the Trypanosomatidae family and specifically leishmaniasis, by means of in vitro assays. The compounds act by reducing the infective and reproductive capacity of the parasites, thereby reducing their survival, and have been shown to be less toxic than the current treatment, meglumine antimoniate (glucantime). These compounds have also been shown to have activity against different species of the genus Leishmania, so the treatment would be broad-spectrum.
The main application of the technology is in the pharmaceutical or veterinary area, as pharmaceutical composition for the treatment of human or animal parasitic diseases. The most remarkable advantages provided by this patent are: - High specificity: the compounds inhibit the iron superoxide dismutase enzyme, that is essential for the survival of parasites from the genus Trypanosoa and Leishmania in the host. - It can be used as a broad-spectrum treatment for diseases caused by the Leishmania genus. - Lower toxicity than reference compounds. - Lower treatment costs and easier to produce - Easily scalable production of the compounds.
Background: Parasites cause a large number of diseases in humans, such as Chagas disease and leishmaniasis, both belonging to the family Trypanosomatidae, ranked by WHO as “forgotten diseases”.
Leishmaniasis is the ninth infectious disease most severe in the world. It is caused by the parasite Leishmania spp., which causes different clinical manifestations and it could be fatal if it is not early treated.
Current treatments for leishmaniasis have low effectiveness and a high number of adverse effects. In addition, there is no effective vaccine against this parasitic disease, which requires the development of new and better treatments.